2,057
Views
8
CrossRef citations to date
0
Altmetric
Research Article

Tacrolimus is effective in relapsed/refractory autoimmune cytopenias: results of a single-center retrospective study

, , , , , & show all

References

  • Takase K, Nagai H, Kadono M, et al. High-dose dexamethasone therapy as the initial treatment for idiopathic thrombocytopenic purpura. Int J Hematol. 2020;111:388–395.
  • Wang L, Xu L, Hao H, et al. First line treatment of adult patients with primary immune thrombocytopenia: a real-world study. Platelets. 2020;31:55–61.
  • Serris A, Amoura Z, Canoui-Poitrine F, et al. Efficacy and safety of rituximab for systemic lupus erythematosus-associated immune cytopenias: A multicenter retrospective cohort study of 71 adults. Am J Hematol. 2018;93:424–429.
  • Norton A, Roberts I. Management of Evans syndrome. Br J Haematol. 2006;132:125–137.
  • Lee YH, Lee HS, Choi SJ, et al. Efficacy and safety of tacrolimus therapy for lupus nephritis: a systematic review of clinical trials. Lupus. 2011;20:636–640.
  • Zheng X, Zhang X, Liu X, et al. Patient with neuromyelitis optica spectrum disorder combined with Sjogren’s syndrome relapse free following tacrolimus treatment. Intern Med. 2014;53:2377–2380.
  • Pan X, Huang F, Pan Z, et al. Treatment of serologically negative Sjogren’s syndrome with tacrolimus: a case report. J Int Med Res. 2020;48(4):300060519893838.
  • Gergis U, Ibrahim M, Al-Kazaz M, et al. Successful treatment with tacrolimus of a patient with severe idiopathic thrombocytopenic purpura after allogeneic bone marrow transplantation. J Clin Oncol. 2012;30:e241–e242.
  • Tabchi S, Hanna C, Kourie HR, et al. Successful treatment of Evans syndrome with tacrolimus. Invest New Drugs. 2015;33:254–256.
  • Gilliland BC, Evans RS. The immune cytopenias. Postgrad Med. 1973;54:195–203.
  • Miano M. How I manage Evans syndrome and AIHA cases in children. Br J Haematol. 2016;172:524–534.
  • Hou M PJ, Shi Y, Zhang C, et al. Mycophenolate mofetil (MMF) for the treatment of steroid-resistant idiopathic thrombocytopenic purpura. Eur J Haematol. 2003;70:353–357.
  • Mckkmbvt V. Cyclosporin A for the treatment of patients with chronic idiopathic thrombocytopenic purpura refractory to corticosteroids or splenectomy. British J Haemotol. 2001;114:121–125.
  • Mahevas M, Fain O, Ebbo M, et al. The temporary use of thrombopoietin-receptor agonists may induce a prolonged remission in adult chronic immune thrombocytopenia. Results of a French observational study. Br J Haematol. 2014;165:865–869.
  • Bylsma LC, Fryzek JP, Cetin K, et al. Systematic literature review of treatments used for adult immune thrombocytopenia in the second-line setting. Am J Hematol. 2019;94:118–132.
  • Takahashi S, Hiromura K, Sakurai N, et al. Efficacy and safety of tacrolimus for induction therapy in patients with active lupus nephritis. Mod Rheumatol. 2011;21:282–289.
  • Halloran PF, Madrenas J. The mechanism of action of cyclosporine: a perspective for the 90s. Clin Biochem. 1991;24:3–7.
  • Miroux C, Morales O, Ghazal K, et al. In vitro effects of cyclosporine A and tacrolimus on regulatory T-cell proliferation and function. Transplantation. 2012;94:123–131.
  • Choudhary DR, Naithani R, Mahapatra M, et al. Efficacy of cyclosporine as a single agent therapy in chronic idiopathic thrombocytopenic purpura. Haematologica. 2008;93:e61–e62. discussion e3.
  • Giovanni E, Giuseppe L, Marcello B. Long-term salvage treatment by cyclosporin in refractory autoimmune haematological disorders. Br J Haematol. 1996;91:341–344.
  • Gonzalez L, Pascual C, Alvarez R, et al. Successful discontinuation of eltrombopag after complete remission in patients with primary immune thrombocytopenia. Am J Hematol. 2015;90:E40–E43.
  • Liu AP, Cheuk DK, Lee AH, et al. Cyclosporin A for persistent or chronic immune thrombocytopenia in children. Ann Hematol. 2016;95:1881–1886.
  • James B, Bussel GC, Mansoor N, et al. Eltrombopag for the treatment of chronic idiopathic thrombocytopenic purpura. N ENGL J MED. 2007;357:2237–2247.
  • Giovanni E, Mario L, Giuseppe L, et al. Long-term salvage therapy with cyclosporin A in refractory idiopathic thrombocytopenic purpura. BLOOD. 2002;99:1482–1485.
  • Agrawal P, Nada R, Ramachandran R, et al. Loss of subpodocytic space predicts poor response to tacrolimus in steroid-resistant calcineurin inhibitor-naive adult-onset primary focal segmental glomerulosclerosis. Indian J Nephrol. 2019;29:90–94.